Shuixin Wang




                                                                                Designing Physician-Verified Clinical AI Platform from Discovery to Deployment—Enabling QuantumLife's First Institutional Customer at Gleneagles Hospital (IHH Healthcare $5.3B Network)       


Role  
Product Strategy Designer
UIUX Designer
Timeline March 2025 - June 2025 Company
QuantumLife
Tool Figma




  1. Overview
Context
When I joined, QuantumLife had genomics technology and potential customer segments. But the founders faced a fundamental question: 'How do we turn this into a product hospitals will purchase and doctors will actually use?' The business stakes is QuantumLife needed to secure its first hospital customer to validate the B2B2C model. Without institutional deployment, the technology—however sophisticated—would remain uncommercial.


The Stakeholder Challenge
Healthcare AI products must satisfy multiple parties with conflicting needs, a challenge intensified by the fragmented longevity medicine infrastructure, where sequencing labs, hospitals, and patients operated in silos.
            
        Hospital Administrators             Procurement teams required centralized oversight and cost control. They couldn't approve a model where individual doctors signed up independently, bypassing institutional budgets and compliance processes. The platform needed hospital-level management.
        DoctorsClinicians needed simple, fast workflows that integrated into their practice. They wouldn't adopt complex enterprise software requiring extensive training. The interface had to feel intuitive while handling genomics complexity behind the scenes.
        QuantumLifeAs an early-stage company, the business needed efficient operations that could scale without proportional cost increases. Supporting each hospital with dedicated staff wasn't sustainable—the architecture had to enable growth.

OutcomeHospital contract signed and platform successfully deployed with clinical team at Gleneagles Hospital Hong Kong—IHH Healthcare's premium network (USD $5.3B revenue, 80+ hospitals across Asia).                    








2.  FINAL OUTCOMES


Doctor Portal 
Gen-Decoder Report  Viewing Page


Omni-Health Page
Other Important Pages

Admin Portal 




3. STRATEGIC CONTEXT
In early 2024, the longevity medicine market hit an inflection point. Driven by aging populations and AI-powered multi-omics breakthroughs, projections showed explosive growth to over $300 billion by 2030.



QuantumLife identified the critical gap: sequencing labs could generate data but lacked clinical interpretation to reach hospitals. Hospitals faced surging demand for longevity services but couldn't afford sequencing infrastructure or specialized interpretation teams. QuantumLife positioned itself as the essential connector, enabling hospitals to deploy longevity medicine without massive infrastructure investment.


To capitalize on this market opportunity, QuantumLife initiated development of Longevity.Omics, a B2B2C platform operationalizing their connector positioning by bridging sequencing labs, QuantumLife's AI-powered analysis, and hospital clinical workflows.


4. PRODUCT DISCOVERY Translating QuantumLife's B2B2C institutional sales strategy into deployable platform system Discovery Objectives



Strategic Outcomes










5. STRATEGIC CONTEXT & DISCOVERY


    Outcome 1: Initial Product Definition Through User Research and Business Strategy 

    Action 1: Defining Product Requirements Through PRD and Physician Interviews



    Based on QuantumLife's strategic objective and initial product scoping documents, the platform needed to serve multiple institutional segments, from large hospital systems requiring centralized oversight to boutique longevity clinics operating with minimal administrative staff.






    However, company documentation outlined high-level business requirements without specifying actual clinical workflows. To translate strategic intent into concrete product requirements, we conducted physician interviews to understand how longevity medicine services would be delivered in practice.

    The interviews revealed clear requirements across two dimensions:



    Outcome 2: From Unified Interface to Dual-Tier Architecture

    Action 1: Hospital Stakeholder Validation and Feedback Collection
















    6. CLINICAL PRODUCT DESIGN & REALIZATION





































    7. BUSINESS IMPACT & DEPLOYMENT